Onderneming NexgenRx Inc. Toronto S.E.
Aandelen
NXG
CA65337X1042
Beleggingsbeheer & Fondsbeheerders
Vakgebied
Verkoop per activiteit
CAD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Administration Fees
45,9
%
| 5 | 35,6 % | 6 | 45,9 % | +39,72% |
Transaction Fees
37,4
%
| 6 | 50,2 % | 5 | 37,4 % | -19,32% |
Consulting
12,1
%
| 2 | 11,9 % | 2 | 12,1 % | +9,71% |
Other
4,0
%
| 0 | 1,6 % | 1 | 4,0 % | +169,38% |
Commission
0,6
%
| 0 | 0,7 % | 0 | 0,6 % | -4,75% |
Verkoop per regio
CAD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Canada
100,0
%
| 13 | 100,0 % | 14 | 100,0 % | +8,33% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ronald Loucks
FOU | Founder | - | 13-03-03 |
Director of Finance/CFO | 61 | 05-12-16 | |
Jason Robinson
ADM | Chief Administrative Officer | - | 01-01-18 |
Mark Payne
CTO | Chief Tech/Sci/R&D Officer | - | 24-08-21 |
Andrew Munroe
COO | Chief Operating Officer | - | 01-02-17 |
Paul Freedman
CTO | Chief Tech/Sci/R&D Officer | - | - |
Doreen Harvey
HRO | Human Resources Officer | - | - |
Avik Debroy
AUD | Comptroller/Controller/Auditor | - | - |
Corporate Secretary | - | 11-06-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ronald Loucks
FOU | Founder | - | 13-03-03 |
Chairman | - | 07-03-06 | |
Charles Burns
BRD | Director/Board Member | - | 16-06-17 |
Randy E. McGlynn
BRD | Director/Board Member | - | 22-08-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 70 921 820 | 44 787 032 ( 63,15 %) | 0 | 63,15 % |
Aandeel B | 0 | 6 600 000 | 0 | 0 |
Bedrijfsgegevens
Sector
Verkoop per activiteit
Vaira. 1 jan. | Kapi. | |
---|---|---|
-4,90% | 115 mld. | |
+9,16% | 101 mld. | |
+11,67% | 67,41 mld. | |
+24,65% | 66,1 mld. | |
+14,52% | 44,58 mld. | |
+14,85% | 43,37 mld. | |
+18,26% | 35,13 mld. | |
+9,42% | 26,31 mld. | |
-2,41% | 22,77 mld. |